Janssen's Olysio/sofosbuvir combination cleared by FDA

6 November 2014
2019_biotech_test_vial_discovery_big

The Food and Drug Administration has approved US health care giant Johnson & Johnson's (NYSE: JNJ) Olysio (simeprevir) in combination with sofosbuvir (Gilead Sciences’ new blockbuster hepatitis C drug Sovaldi) as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C infection in adult patients as part of a combination antiviral treatment regimen.

The supplemental New Drug Application was filed in May by J&J subsidiary Janssen Research & Development, which developed Olysio – which is already approved and marketed for hepatitis C - with Swedish drugmaker Medivir (OMX: MVIR).

Supporting data for the approval

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology